Molecular monitoring of BAALC expression in patients with CD34-positive acute leukemia

Recent studies have shown that high BAALC expression predicts an adverse prognosis and may define an important risk factor in acute myeloid leukemia patients with normal karyotype. We performed, using real-time quantitative reverse transcriptase polymerase chain reaction (RQ-PCR), the molecular anal...

Full description

Saved in:
Bibliographic Details
Published in:International journal of hematology 2010-05, Vol.91 (4), p.636-645
Main Authors: Najima, Yuho, Ohashi, Kazuteru, Kawamura, Machiko, Onozuka, Yuji, Yamaguchi, Toshikazu, Akiyama, Hideki, Sakamaki, Hisashi
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Aged, 80 and over
Antigens, CD34 - metabolism
Biological and medical sciences
Biomarkers, Tumor - genetics
Disease-Free Survival
Female
Gene Expression Regulation, Leukemic
Hematologic and hematopoietic diseases
Hematology
Humans
Kaplan-Meier Estimate
Leukemia, Myeloid, Acute - genetics
Leukemia, Myeloid, Acute - mortality
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Male
Medical sciences
Medicine
Medicine & Public Health
Middle Aged
Neoplasm Proteins - genetics
Neoplasm, Residual - genetics
Neoplasm, Residual - mortality
Oncology
Original Article
Predictive Value of Tests
Prognosis
Reverse Transcriptase Polymerase Chain Reaction
Risk Factors
RNA, Messenger - genetics
Translocation, Genetic
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recent studies have shown that high BAALC expression predicts an adverse prognosis and may define an important risk factor in acute myeloid leukemia patients with normal karyotype. We performed, using real-time quantitative reverse transcriptase polymerase chain reaction (RQ-PCR), the molecular analysis of BAALC gene as a possible minimal residual disease (MRD) marker in 45 patients with newly diagnosed acute leukemia. BAALC transcript levels in 32 patients with CD34 expressed in leukemic blasts were 2–3 logs higher than background levels, and the copy number was reduced in patients achieving hematological remission. Comparative monitoring of MRD by RQ-PCR for the Wilms’ tumor gene 1( WT1 ) or specific translocation markers demonstrated that BAALC had similar kinetics as WT1 , AML1/ETO and minor BCR/ABL , but not PML/RARA . Quantitation of BAALC gene expression made it possible to assess MRD in patients with CD34-positive acute leukemia. To our knowledge, this is the first report concerning the use of BAALC mRNA expression for MRD monitoring.
ISSN:0925-5710
1865-3774
DOI:10.1007/s12185-010-0550-8